Okyo Pharma receives feedback from FDA Type D meeting on urcosimod pathway
Okyo Pharma announced feedback from its FDA Type D meeting, validating the company's regulatory and clinical path forward for urcosimod and supporting advancement into a global Phase 3 pivotal trial for NCP. The FDA feedback provides increased clarity around the company's updated regulatory strategy, reducing uncertain